Matches in Wikidata for { <http://www.wikidata.org/entity/Q37093540> ?p ?o ?g. }
- Q37093540 description "article científic" @default.
- Q37093540 description "article scientifique" @default.
- Q37093540 description "articolo scientifico" @default.
- Q37093540 description "artigo científico" @default.
- Q37093540 description "artículu científicu espublizáu en mayu de 2013" @default.
- Q37093540 description "bilimsel makale" @default.
- Q37093540 description "scientific article published on May 2013" @default.
- Q37093540 description "vedecký článok" @default.
- Q37093540 description "vetenskaplig artikel" @default.
- Q37093540 description "videnskabelig artikel" @default.
- Q37093540 description "vědecký článek" @default.
- Q37093540 description "wetenschappelijk artikel" @default.
- Q37093540 description "wissenschaftlicher Artikel" @default.
- Q37093540 description "наукова стаття, опублікована в травні 2013" @default.
- Q37093540 description "научни чланак" @default.
- Q37093540 description "مقالة علمية نشرت في مايو 2013" @default.
- Q37093540 name "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 name "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 type Item @default.
- Q37093540 label "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 label "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 prefLabel "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 prefLabel "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 P1433 Q37093540-FEF36733-32E8-41F4-A702-1AD153854B72 @default.
- Q37093540 P1476 Q37093540-336D8E26-54F0-49A3-BFCA-18389EDE6571 @default.
- Q37093540 P2093 Q37093540-17FCAC6E-E7BD-4471-995F-AFD2095984E0 @default.
- Q37093540 P2093 Q37093540-3ED3450B-C0BC-44C7-BE1B-A4EB8EEE889F @default.
- Q37093540 P2093 Q37093540-44F06F3B-23E0-49E2-AD8E-370FA7A9FAB5 @default.
- Q37093540 P2093 Q37093540-5AB63110-1FC1-44C0-8414-D3624FA7393B @default.
- Q37093540 P2093 Q37093540-5AC3DF29-046B-4276-B55D-B1AD7C4E06D6 @default.
- Q37093540 P2093 Q37093540-73D68FA0-300D-4AAA-94BE-E62C9A13E713 @default.
- Q37093540 P2093 Q37093540-819D2E6A-53B9-41E7-9CBE-FA6DD3FB3D5B @default.
- Q37093540 P2093 Q37093540-FF6829E9-D9BB-4F03-84A6-F0C1194BDB01 @default.
- Q37093540 P2860 Q37093540-00A38E02-526F-4318-A908-EB67018B8CFE @default.
- Q37093540 P2860 Q37093540-0E867D09-2181-4032-A8AC-9831FA16DB69 @default.
- Q37093540 P2860 Q37093540-0F7E0B8A-8A41-4314-AEDC-6EAB587F86C5 @default.
- Q37093540 P2860 Q37093540-113EFE01-ADF3-4E09-83B1-01A3AF15EA05 @default.
- Q37093540 P2860 Q37093540-167C8858-5CC6-4A20-B870-5348FA6F79F7 @default.
- Q37093540 P2860 Q37093540-24F466A8-5A9E-475A-9286-AF6668B7DD8F @default.
- Q37093540 P2860 Q37093540-2DBB9678-0CB8-4B34-AD18-52BC127AD86B @default.
- Q37093540 P2860 Q37093540-31C2FF6C-5798-4B1A-B277-F3FFE3A09FC4 @default.
- Q37093540 P2860 Q37093540-34BACA6D-55D4-41C9-8DFF-C0BDAFE322C8 @default.
- Q37093540 P2860 Q37093540-41F0CF00-2AB4-4E65-8FF0-98F59BA6861C @default.
- Q37093540 P2860 Q37093540-4B79FACE-AC35-42B7-9B96-715BF614B722 @default.
- Q37093540 P2860 Q37093540-50C0E6F5-ED66-4A03-9BFF-AC9D48C259D4 @default.
- Q37093540 P2860 Q37093540-51FD92E0-D9CC-4E10-8D93-FCF0300A7FCA @default.
- Q37093540 P2860 Q37093540-54F2D236-3638-4384-B4D2-B97025ADDE32 @default.
- Q37093540 P2860 Q37093540-57207912-883D-4DD2-92AB-2168F3C6F7A3 @default.
- Q37093540 P2860 Q37093540-5D0D25F7-B52A-4D31-AF41-474DF7382BDD @default.
- Q37093540 P2860 Q37093540-601E2311-34E8-4D75-BE62-B7422011E5DE @default.
- Q37093540 P2860 Q37093540-625EFA79-65CB-4AA6-9C63-7E34CFA044F9 @default.
- Q37093540 P2860 Q37093540-660725C6-5292-4078-A1E8-BFCF06E5F3D5 @default.
- Q37093540 P2860 Q37093540-7419BB79-ED5B-4156-83B3-323434B3913B @default.
- Q37093540 P2860 Q37093540-79F66FED-7388-49C2-8AF3-9B4010679E6D @default.
- Q37093540 P2860 Q37093540-7D1C0091-E9C7-4515-8A9C-E4FABD697CC6 @default.
- Q37093540 P2860 Q37093540-7D7F0BC3-D61E-469A-8BC3-5DD2D65D8B36 @default.
- Q37093540 P2860 Q37093540-8BB4B311-8D99-45FE-A53C-2DEEA957C05D @default.
- Q37093540 P2860 Q37093540-8CC246AB-EB97-46D1-BD13-828C5EF2B5E1 @default.
- Q37093540 P2860 Q37093540-967BA631-B655-4776-97FF-0F2811524731 @default.
- Q37093540 P2860 Q37093540-9A2A3C9D-6E73-4561-B559-F080EB17A99C @default.
- Q37093540 P2860 Q37093540-9C3C7AB8-8D76-43C5-8DD4-23B300CFDBEC @default.
- Q37093540 P2860 Q37093540-9C748512-6BF5-4249-90B9-548C50395F19 @default.
- Q37093540 P2860 Q37093540-AB779AB2-D0B3-4DE0-819A-3DF64EABED6B @default.
- Q37093540 P2860 Q37093540-AB933BB0-56CE-41FB-8F34-6706B054F890 @default.
- Q37093540 P2860 Q37093540-B6ABD4B9-4319-48AF-B3BD-1F7DF98B6CE1 @default.
- Q37093540 P2860 Q37093540-B78FFC59-8D50-4385-839B-841893862747 @default.
- Q37093540 P2860 Q37093540-C5C12D8B-9C95-4D21-9AF6-69FC714411D4 @default.
- Q37093540 P2860 Q37093540-C64C700F-EF44-48AA-BBB0-76CAB41FB8E1 @default.
- Q37093540 P2860 Q37093540-D4E94E3B-0DEE-4AA9-B269-0DF5842BCE5F @default.
- Q37093540 P2860 Q37093540-D7124613-8F37-4621-AC7B-E961192D9092 @default.
- Q37093540 P2860 Q37093540-D888FAAF-F25A-4B16-BDC8-2551DA93B4E3 @default.
- Q37093540 P2860 Q37093540-DF7415F1-4FA6-4A1E-9EB8-5D141CD107CF @default.
- Q37093540 P2860 Q37093540-E03553F4-3C53-4740-B32D-EFD1A1248CBE @default.
- Q37093540 P2860 Q37093540-E3935FCD-3B42-4B45-A10E-E155954F947C @default.
- Q37093540 P2860 Q37093540-E64F77EA-A638-4711-8CDC-2E9EFC07FE51 @default.
- Q37093540 P2860 Q37093540-EB2F63D1-2288-4F5E-9585-FED9591D82BD @default.
- Q37093540 P2860 Q37093540-F09EDDA4-E4D8-4FF5-8A10-5D6A138D2AE8 @default.
- Q37093540 P2860 Q37093540-FB938927-76DB-4789-9084-B084C953B625 @default.
- Q37093540 P2860 Q37093540-FF6BC606-7CA3-4534-B17A-EA5FFD374815 @default.
- Q37093540 P304 Q37093540-6979A439-14B1-47A5-9079-84968A61116E @default.
- Q37093540 P31 Q37093540-FB2E4C13-28F6-4A1D-A1A3-1F4E8CBA5CBC @default.
- Q37093540 P356 Q37093540-016D0C2F-D056-4F22-9DEE-296A4F257F56 @default.
- Q37093540 P407 Q37093540-36052810-D527-4984-9D43-2600F6138DE8 @default.
- Q37093540 P433 Q37093540-64089FD3-C318-4AA4-BA4F-1241286169C1 @default.
- Q37093540 P478 Q37093540-B864A19D-93C1-4C15-BC4E-22A185B67E1F @default.
- Q37093540 P50 Q37093540-6754C0C7-B8A5-4C93-9CD7-ECAE734D2087 @default.
- Q37093540 P50 Q37093540-89EEA063-5852-4050-9BB4-140CAF688F89 @default.
- Q37093540 P50 Q37093540-D9A193FA-D582-455E-8942-44FA489BFD62 @default.
- Q37093540 P50 Q37093540-E9C20C6E-FD93-459E-93C1-706E585C45DD @default.
- Q37093540 P577 Q37093540-DC3D29EF-7F6B-4968-AF08-EFE52FF04881 @default.
- Q37093540 P5875 Q37093540-66AAE350-A03B-4DDB-A36D-12136179770D @default.
- Q37093540 P698 Q37093540-191492F2-9473-465C-A513-528D56DCFBA5 @default.
- Q37093540 P921 Q37093540-B229526F-77B5-4152-B9D2-3536172BFD77 @default.
- Q37093540 P932 Q37093540-4B812CFF-1DC4-4A90-A1F9-134ECFC45254 @default.
- Q37093540 P356 ONCOTARGET.974 @default.
- Q37093540 P698 23670029 @default.
- Q37093540 P1433 Q1573155 @default.
- Q37093540 P1476 "P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy" @default.
- Q37093540 P2093 "Carla L Warneke" @default.
- Q37093540 P2093 "David S Hong" @default.